Pluripotent Stem Cells and Gene Therapy

Mathew G. Angelos, Fahad Kidwai, Dan S. Kaufman

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Over the past decade, our understanding of stem cell biology has rapidly expanded with the discovery that any mammalian somatic cells can be genetically reprogrammed into a pluripotent state with the potential to differentiate into any cell lineage. Induced pluripotent stem cells (iPSCs) have revolutionized current experimental approaches for understanding the pathophysiological underpinnings of diseases with genetic etiologies. While the translational potential of human iPSCs to correct genetic diseases is great, there is yet no consensus on how to maximize human iPSC production while minimizing negative off-target effects, such as tumorigenesis or immunogenicity of transplanted cells. In this chapter, we will summarize the various reprogramming factor requirements and gene delivery methodologies that have been employed in generating human pluripotent stem cells. We will further focus on the clinical translation of human iPSC technology by discussing how it can be used to model disease as a cell-source for drug discovery and as a direct therapy for reversing phenotypes caused by genetic diseases.

Original languageEnglish (US)
Title of host publicationTranslating Gene Therapy to the Clinic
Subtitle of host publicationTechniques and Approaches
PublisherElsevier Inc.
Number of pages16
ISBN (Electronic)9780128005644
ISBN (Print)9780128005637
StatePublished - Jan 1 2015


  • Cell therapy
  • Gene therapy
  • Genetic disease models
  • Induced pluripotent stem cells
  • Pharmaceutical testing
  • Pluripotency
  • Reprogramming


Dive into the research topics of 'Pluripotent Stem Cells and Gene Therapy'. Together they form a unique fingerprint.

Cite this